MASI, GIANLUCA Statistiche

MASI, GIANLUCA  

DIPARTIMENTO DI RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 305 (tempo di esecuzione: 0.052 secondi).
Titolo Data di pubblicazione Autore(i) File
5 FU + Irinotecan 1-gen-2003 Falcone, Alfredo; Masi, G.; Cupini, S.; Cerri, E.; Allegrini, G.
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer 1-gen-2001 Falcone, Alfredo; Allegrini, G; Masi, G; Lencioni, M; Pfanner, E; Brunetti, I; Danesi, Romano; Bocci, Guido; DEL TACCA, M; Conte, P.
5-fluorouracil administered as a 48-hours semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin 1-gen-2004 Allegrini, G.; Falcone, Alfredo; DI MARSICO, R.; Lencioni, M.; Masi, G.; Galli, C.; Cupini, S.; Pfanner, E.; Marcucci, L.
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 1-gen-2008 Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo
A multicenter, randomized phase III study of second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients who progressed to a first-line treatment containing bv: results from the bebyp trial by the Gruppo Oncologico Nord Ovest (GONO). 1-gen-2012 Salvatore, L; Masi, G; Loupakis, F; Cremolini, Chiara; Schirripa, M; Fornaro, L; Antoniotti, C; Vivaldi, C; Granetto, C; Fea, E; Antonuzzo, L; Giommoni, E; Boni, C; Banzi, M; Chiara, S; Sonaglio, C; Allegrini, G; Marcucci, L; Valsuani, C; Greco, F; Safina, V; Boni, L; Falcone, Alfredo
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 1-gen-2008 Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed 1-gen-2004 Masi, G; Falcone, Alfredo; DI PAOLO, Antonello; Allegrini, G; Danesi, Romano; Barbara, C; Cupini, S; DEL TACCA, Mario
A PHASE ii TRIAL OF FIXED-DOSE RATE GEMCITABINE PLUS CAPECITABINE IN METASTATIC/ADVANCED BILIARY TRACT CANCER PATIENTS. 1-gen-2012 Santini, D; Virzì, V; Vasile, E; Vincenzi, B; Catalano, V; Graziano, F; Masi, G; Bronte, G; Russo, A; Falcone, Alfredo; Tonini, G.
About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial” 1-gen-2020 Bargellini, I.; Vivaldi, C.; Crocetti, L.; Masi, G.
About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial” 1-gen-2020 Bargellini, I.; Vivaldi, C.; Crocetti, L.; Masi, G.
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. 1-gen-2018 Cremolini, C; Antoniotti, Carlotta; Lonardi, S; Aprile, G; Bergamo, F; Masi, G; Grande, R; Tonini, G; Mescoli, C; Cardellino, Gg; Coltelli, L; Salvatore, Lisa; Corsi, Dc; Lupi, C; Gemma, D; Ronzoni, M; Dell'Aquila, E; Marmorino, F; Di Fabio, F; Mancini, Ml; Marcucci, L; Fontanini, G; Zagonel, V; Boni, L; Falcone, A
Adjuvant sistemy chemotherapy after putative curative resection of colorectal liver and lung metastases. 1-gen-2013 Brandi, G.; Derenzini, E.; Falcone, Alfredo; Masi, G.; Loupakis, Fotios; Pietrabissa, A.; Pinna, A. D.; Ercolani, G.; Pantaleo, M. A.; Di Girolamo, S.; Grazi, G. L.; De Rosa, F.; Biasco, G.
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 1-gen-2021 Rapposelli, I. G.; Tada, T.; Shimose, S.; Burgio, V.; Kumada, T.; Iwamoto, H.; Hiraoka, A.; Niizeki, T.; Atsukawa, M.; Koga, H.; Hirooka, M.; Torimura, T.; Iavarone, M.; Tortora, R.; Campani, C.; Lonardi, S.; Tamburini, E.; Piscaglia, F.; Masi, G.; Cabibbo, G.; Giuseppe Foschi, F.; Silletta, M.; Tsuji, K.; Ishikawa, T.; Takaguchi, K.; Kariyama, K.; Itobayashi, E.; Tajiri, K.; Shimada, N.; Shibata, H.; Ochi, H.; Yasuda, S.; Toyoda, H.; Fukunishi, S.; Ohama, H.; Kawata, K.; Tani, J.; Nakamura, S.; Nouso, K.; Tsutsui, A.; Nagano, T.; Tanaka, T.; Itokawa, N.; Okubo, T.; Arai, T.; Imai, M.; Joko, K.; Koizumi, Y.; Hiasa, Y.; Rimini, M.; Ratti, F.; Aldrighetti, L.; Cascinu, S.; Casadei-Gardini, A.
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients 1-gen-2012 Crea, F; Fornaro, L; Paolicchi, E; Masi, G; Frumento, P; Loupakis, F; Salvatore, L; Cremolini, C; Schirripa, M; Graziano, F; Ronzoni, M; Ricci, V; Farrar, Wl; Falcone, A; Danesi, R
AN EZH2 POLYMORPHISMS IS ASSOCIATED WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS. 1-gen-2012 Crea, F; Fornaro, L; Paolicchi, E; Masi, G; Frumento, P; Loupakis, F; Salvatore, L; Cremolini, Chiara; Schirripa, M; Graziano, F; Ronzoni, M; Ricci, V; Farrar, Wl; Falcone, Alfredo; Danesi, Romano
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 1-gen-2013 Schirripa, M; Loupakis, F; Cremolini, Chiara; Morvillo, M; Bergamo, F; Zoratto, F; Salvatore, L; Antoniotii, C; Marmorino, F; Sensi, E; Lupi, C; Fontanini, Gabriella; DE GREGORIO, V; Giannini, R; Basolo, F; Masi, G; Falcone, Alfredo
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 1-gen-2008 Loupakis, F.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Falcone, Alfredo
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 1-gen-2020 Faloppi, L.; Puzzoni, M.; Casadei Gardini, A.; Silvestris, N.; Masi, G.; Marisi, G.; Vivaldi, C.; Gadaleta, C. D.; Ziranu, P.; Bianconi, M.; Loretelli, C.; Demurtas, L.; Lai, E.; Giampieri, R.; Galizia, E.; Ulivi, P.; Battelli, N.; Falcone, A.; Cascinu, S.; Scartozzi, M.
Anti-HER agents in gastric cancer: from the bench to bedside through biology 1-gen-2011 Fornaro, L.; Lucchesi, M.; Caparello, C.; Vasile, E.; Caponi, S.; Ginocchi, L.; Masi, G.; Falcone, Alfredo
Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings 1-gen-2020 Gabelloni, Michela; Di Nasso, Matteo; Morganti, Riccardo; Faggioni, Lorenzo; Masi, Gianluca; Falcone, Alfredo; Neri, Emanuele